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A B S T R A C T
Rationale and objective: More than 20 years after cytology-based screening was introduced in Central and
South America (CSA), cervical cancer remains a leading cause of cancer incidence and mortality in the
region. Although several population-based registries exist in the region, few comprehensive analyses
have been conducted to describe the status of cervical cancer control.
Methods: Population-based data from cancer registries in 13 countries and mortality data from
18 countries in CSA were analyzed. Standardized incidence and mortality rates were estimated and time
trend analysis performed when information was available. In addition, a search of available data on HPV
vaccination and cervical cancer screening was carried out.
Results: Cervical cancer incidence and mortality have decreased in some CSA countries, with an annual
percentage change from 4.2 to 6.7 for incidence and 0.2 to 8.3 for mortality. In total, seven
countries have age-standardized mortality rates over 10 per 100,000 women, generally corresponding to
those with the lowest income levels. All countries have implemented screening programs with different
extents of coverage and levels of organization. To date, nine countries have introduced HPV vaccination in
national immunization programs.
Conclusions: Despite incidence declines observed in some countries, cervical cancer mortality remained
almost stable in most countries in the region. Decreases in mortality trends in Chile and Costa Rica are
probably the result of early detection programs. Better organized programs might favor greater impact on
cancer incidence and mortality, but technological developments offer more suitable opportunities for
prevention and alternative approaches for screening of precancerous lesions.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Cervical cancer is the fourth most common cancer in women
worldwide, with approximately 530,000 cases per year and$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).270,000 deaths occurring in 2012 [1]. Despite overall declining
trends, there are signiﬁcant differences between countries, and the
total number of cases is expected to increase in the next few
decades as a consequence of demographic change.
Cervical cancer predominantly affects families in the lower
socioeconomic groups, with a very large proportion of all cases
worldwide (85%) occurring in developing countries [1]. The reason
for this is mainly lack of access to health services, including
screening and treatment of precancerous lesions, which has largely
reduced cervical cancer incidence and mortality in developed
countries in the last 50 years [2].
The main cause of cervical cancer  namely persistent infection
with sexually transmitted human papillomavirus (HPV)  has been
clearly established, opening the way to new primary and secondary
prevention strategies. Vaccination of adolescent women and
screening of adult women with HPV tests followed by appropriate. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
Table 1
Countries included in the analysis of time trends.
Country Name of registries included Period % of the national population covered
Argentina Bahia Blanca 1993–2007 0.8
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 1997–2006 8.0
Chile Valdivia 1993–2008 2.2
Costa Rica National registry 1985–2007 100.0
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has generated a realistic expectation for cervical cancer control in
the near future, if the political will and resources are available.
Central and South America (CSA), with nearly 600 million
inhabitants, continue to bear an important burden of cervical
cancer. According to data from GLOBOCAN 2012 [1], there were
approximately 64,000 new cases of invasive cancer and
26,000 deaths in CSA, making the disease the ﬁrst or second
most frequent cancer among women in many countries in the
region. Recent projections indicate almost a doubling in the
number of cases in the next 15 years unless active interventions are
established or improved [2].
The CSA region has contributed extensively to our knowledge of
cervical cancer epidemiology and control. At least three major
cohort studies on the natural history of the disease have been
conducted in the region [3], and numerous women from this area
have participated in clinical trials during the development of HPV
vaccines [4]. Cytology-based screening activities have been
implemented in most CSA countries, some of which started as
long as ﬁve decades ago [5]. However, the success of these
programs has been very limited in a region with the highest social
disparities in the world [6], where socioeconomic and health-
system determinants still play a major role in the causal web of
cervical cancer mortality.
We describe the trends and the current situation in cervical
cancer incidence and mortality in Central and South America. We
reviewed the status of preventive interventions in an effort to
better understand the achievements and limitations of cervical
cancer control in the region.
2. Methods
The present analysis includes cervix uteri cancer (C53), as coded
by the 10th edition of the International Classiﬁcation of Diseases
for Oncology (ICD-10). The data sources and methods are described
in detail in another article in this issue. In brief, we used the
geographic boundaries for the CSA region according to the United
Nations deﬁnition. All cancer registries included in the Interna-
tional Agency for Research on Cancer database and member
organizations of the International Association of Cancer Registries
(IACR) and the Red de Institutos Nacionales de Cancer (RINC) were
invited to participate in this project. Although Cuba is located
within the Caribbean, it was included in this project because it has
member registries within the IACR and is part of the RINC. We
obtained regional- and national-level incidence data from 48
population-based cancer registries in 13 countries and nationwide
cancer deaths from the World Health Organization mortality
database for 18 countries. Incidence and mortality data were
available from most CSA countries (including Cuba) except in
Honduras and Guyana where neither incidence nor mortality data
were available; French Guyana and Bolivia where only incidence
data were available; and Belize, Guatemala, Nicaragua, Panama,
Paraguay, Suriname, and Venezuela where only mortality data
were available. We estimated age-standardized incidence (ASR)
and mortality (ASMR) rates per 100,000 person-years using thedirect method and the world standard population [1,7,8]. We
estimated national ASRs by aggregating the data from the available
cancer registries using a weighted average of local rates. Registries
that provided formal consent to use data by individual year of
diagnosis for 10-years were included in the time-trend analysis
(shown below). To describe incidence and mortality time trends,
we calculated the estimated annual percentage change (EAPC) for
the most recent 10-year period using the method proposed by
Esteve et al. [2,9]. Trends in incidence and EAPCs were estimated
for four countries (Table 1). All of the EAPCs were tested for
equality to zero by using the corresponding standard errors. We
considered EAPCs statistically signiﬁcant if the P-value 0.05. We
used reallocation methods to separate cervix and corpus uteri from
imprecisely coded uterine cancer deaths [10]. We conducted the
data analysis in Stata version 12.1 (StataCorp).
Using the cancer registry data, we also estimated incidence
rates by histological subtype as presented in Cancer Incidence in
Five Continents (CI5) volume X [11].
To describe the status of disease control we used the latest
report by the Pan American Health Organization about existing
programs for HPV vaccination and cervical cancer screening in the
region [12]. We searched data about HPV vaccine coverage in the
WHO monitoring system for immunization programs; however, no
data on HPV vaccine coverage were found. Information about
screening coverage was gathered from ofﬁcial reports of national
population-based surveys; if the ofﬁcial reports did not contain
detailed data on the subject we used scientiﬁc papers based on the
surveys and published in peer-reviewed journals.
3. Results
3.1. Burden of disease
Cervical cancer was the leading female cancer diagnosis in El
Salvador and Bolivia and the second leading female cancer in
Mexico, Argentina, Colombia, Ecuador, French Guyana, and Peru. In
ﬁve out of 20 countries, cervical cancer was the leading cause of
female cancer mortality, while in most countries it was the second
and third cause of cancer deaths. Notably, it was only the sixth
cause of cancer death among women in Chile and the fourth in
Costa Rica and Cuba.
The highest incidence was observed in French Guyana and El
Salvador (ASR 29.7 and 28.9 per 100,000), while Costa Rica, Chile,
Mexico and Cuba showed rates under 15 per 100,000 (Table 2). The
highest mortality rates (per 100,000) were observed in Belize and
Paraguay (17.4 and 15.3, respectively), and in descending order: El
Salvador, Nicaragua, Venezuela, Suriname, and Ecuador, with rates
between 10 and 15 per 100,000. The lowest mortality was observed
in Chile, Uruguay, Brazil and Costa Rica (rates ranging from 6.0 to
7.3) (Table 2).
The age-speciﬁc pattern for incidence rates was similar for all
countries investigated, with incidence increasing rapidly after the
age of 30 years, a peak around the age of 40 years, and a subsequent
plateau that goes into older ages. Mortality shows a similar pattern,
but there is a constant increase with increasing age, particularly for
Table 2
Incidence and mortality rates in Central and South American countries (including all ages).
Country Period Incidence Mortality
Cases Crude Rate ASR (W) Cum. Rate MV% Ranka Deaths Crude Rate ASR (W) Cum. Rate Ranka
Argentinab 2003–2007 2379 18.4 17.5 1.78 89 2 9734 9.9 8.0 0.85 3
Belize 2003–2007 81 11.4 17.4 1.79 1
Boliviab 2011 283 20.9 22.2 2.34 98 1
Brazilb 2003–2007 11257 18.3 18.2 1.98 91 3 31787 6.7 6.8 0.76 2
Chileb 2003–2007 347 15.6 13.9 1.39 90 3 3728 9.1 7.3 0.79 6
Colombiab 2003–2007 2159 21.5 20.2 2.19 94 2 9682 8.9 9.9 1.12 3
Costa Rica 2003–2007 1465 14.0 13.9 1.40 90 3 629 5.9 6.0 0.61 4
Cubab 2004–2007 230 14.3 10.6 1.01 99 4 2748 12.3 8.8 0.95 4
Ecuadorb 2003–2007 942 18.3 19.8 2.15 96 2 3014 9.0 10.4 1.09 2
El Salvadorb 1999–2003 3418 23.8 28.9 3.22 98 1 1847 11.9 14.5 1.60 1
French Guyanab 2003–2008 117 23.4 29.7 3.29 98 2
Mexicob 2006–2010 1850 10.5 11.0 1.16 100 2 21428 7.2 9.2 0.88 3
Nicaragua 2003–2007 1196 8.8 13.2 1.47 1
Panama 2003–2007 686 8.5 9.0 0.92 2
Paraguay 2003–2007 1700 11.7 15.3 1.68 1
Perub 2001–2005 2102 21.9 22.2 2.41 95 2 5224 7.8 9.4 1.00 2
Suriname 2003–2007 133 10.7 11.3 1.27 1
Uruguay 2005–2007 1049 20.4 17.1 1.68 91 3 549 10.6 7.2 0.75 3
Venezuela 2003–2007 7610 11.5 13.0 1.39 1
ASR (W), age-standardized (World population) rate per 100,000; Cum., cumulative; MV, microscopic veriﬁcation.
a Rank across cancer types, based on highest ASR excluding: All sites but C44 and All sites.
b Incidence rates were estimated using aggregated data from regional cancer registries.
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for adolescents and young women (15–25 years old) between
1.0 and 10.0 per 100,000, and the corresponding mortality was
below or around 1.0 per 100,000.
The cumulative incidence rate of cervical cancer in 2003–
2007 among females (0–74 years old) ranged between 1.01% and
3.21% (Table 2). In the absence of other causes of death, the
cumulative mortality rate of cervical cancer in 2003–2007 in
females was between 0.78% and 1.79%. Females in El Salvador,
Bolivia, French Guyana and Peru experienced the highest
cumulative incidence rates in the region, while Belize, El Salvador
and Paraguay had the highest cumulative mortality rates (Table 2).
Incidence of cervical cancer in Argentina (1998–2007), Brazil
(1997–2006), Chile (1997–2008), and Costa Rica (1985–2007)
steadily decreased during early periods, followed by a sharp
decline after the mid–2000 s with incidence declining between
4.2% per year in Brazil to 6.7% in Argentina (P < 0.05). Mortality
rates declined on average by 8.3% per year in Costa Rica (P < 0.05)
and 4.4% per year in Chile (P 0.05), while in Brazil and Argentina
rates remained unchanged (>0.05%) (Fig. 2).
Approximately 93% of all cervical cancer cases diagnosed in CSA
countries were carcinomas; 6.8% were unspeciﬁed, 0.23% were
sarcomas, and 0.14% were others (Table 3). Squamous-cell
carcinoma was the most common cervical cancer type diagnosed,
representing between 65% (Cuba) and 94% (French Guyana) of all
cervical cancers, followed by adenocarcinoma (ranging from 3% in
French Guyana to 14% in Brazil) and unspeciﬁed cervical tumors
(ranging from 0% in Mexico to 14% in Costa Rica).
The age-standardized incidence rate (per 100,000) of squa-
mous-cell carcinoma in females was remarkably high in French
Guyana (28.1) and El Salvador (25.7), followed by Bolivia (19.0),
Peru (17.3), Ecuador (15.5), and Colombia (14.8). The rates of the
remaining carcinomas were noticeably lower: adenocarcinoma
ranged between 1.0 and 2.7, “other” between 0.14 and 2.5, and
unspeciﬁed cervical tumors between 0.09 and 0.46. There is a
decline in squamous-cell carcinomas and only a small decrease in
adenocarcinomas (Fig. 3).3.2. Cervical cancer prevention
Eight out of 18 countries in Central and South America have
implemented HPV vaccination among girls as of 2014 (Table 4). The
targeted age for vaccination ranged from 9 to 13 years, although
Colombia and Mexico deﬁned the target cohort by school grade
rather than by age range. In general, the vaccination schedule
corresponds to that indicated by the vaccine manufacturer.
However, Colombia and Brazil are using an extended schedule
with three doses at 0, 6, and 60 months; Mexico and Chile are using
two doses (0–6 months) [13]. The delivery strategy in Uruguay is
focused on health centers, while the remaining countries use a
school-based strategy (Peru, Paraguay, and Colombia) or a
combination of schools and health centers (Argentina, Brazil,
Mexico and Panama). Given the recent introduction of HPV
vaccination (Mexico and Panama introduced the vaccine in 2008,
the earliest programs in the region), no ofﬁcial reports were found
on vaccine coverage. In a rapid assessment survey conducted by
the Pan American Health Organization in 2013, Mexican and
Panamanian governments reported a coverage of 67% for the third
vaccination dose in their target populations [12].
All countries in the region have implemented cytology-based
screening to some extent, and some of the countries that have
implemented HPV vaccination have also introduced HPV screening
tests for cervical cancer screening (Table 4). Moreover, several
countries experiencing low screening coverage have introduced
visual inspection with acetic acid (VIA) as a component of see-and-
treat programs, including Colombia, where this technique (in
combination with visual inspection with lugol iodine) has been
proposed for rural communities with low access to health care
[12].
Only Chile declares having an organized screening program
[14]; however, Argentina, Brazil, and Colombia show similar or
higher screening coverage than Chile (Table 4). Follow-up rates
among women with a positive screening tests varies extensively;
countries with national data – like Chile and Cuba – revealed
follow-up rates of >90% for women with a high-grade squamous
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Fig. 2. Estimated annual percentage change in incidence and mortality of cervical cancer for selected Central and South American countries.
Table 3
Cervical cancer incidence rates by histological type (all ages).
Country
(Period)
Carcinoma Sarcoma Other Unspeciﬁed
Squamous cell Adenocarcinoma Other Unspeciﬁed
n ASR MV (%) n ASR MV (%) n ASR MV (%) n ASR MV (%) n ASR MV (%) n ASR MV (%) n ASR MV (%)
CENTRAL AMERICA
Costa Rica
(2003–07)
1027 9.8 100 172 1.7 100 29 0.30 100 31 0.29 100 4 0.05 100 0 – – 202 1.9 25
Cubay
(2004–07)
149 6.8 100 24 1.0 100 52 2.5 100 1 0.09 100 0 – – 0 – – 4 0.22 25
El Salvadora
(1999–03)
3038 25.7 100 241 2.1 100 16 0.14 100 54 0.46 100 2 0.02 100 2 0.02 100 65 0.52 3
Mexicoa
(2005–10)
1902 9.6 100 272 1.4 100 103 0.53 100 82 0.41 100 2 0.01 100 2 0.01 100 0 – –
SOUTH AMERICA
Argentinaa
(2003–07)
1723 12.7 94 194 1.4 95 292 2.1 93 16 0.12 100 5 0.03 100 1 0.01 100 148 1.0 17
Boliviaa
(2011)
243 19.0 100 23 1.9 100 12 0.93 100 0 – – 0 – – 0 – – 5 0.42 0
Brazila
(2003–07)
7569 12.3 100 1560 2.5 99 934 1.5 90 124 0.20 99 38 0.06 97 27 0.05 96 1005 1.6 11
Chilea
(2003–07)
245 9.9 100 40 1.6 100 14 0.53 100 5 0.17 100 3 0.13 100 2 0.08 100 38 1.5 11
Colombiaa
(2003–07)
1573 14.8 100 283 2.7 100 118 1.1 100 29 0.27 100 5 0.05 100 2 0.02 100 149 1.3 11
Ecuadora
(2003–07)
733 15.5 100 94 2.0 100 58 1.2 100 17 0.35 100 2 0.06 100 0 – – 38 0.71 11
French Guyanaa
(2003–07)
110 28.1 100 4 0.9 100 1 0.22 100 0 – – 0 – – 0 – – 2 0.48 0
Perua
(2001–05)
1644 17.3 100 198 2.2 100 63 0.61 97 22 0.23 100 3 0.03 100 2 0.02 100 170 1.8 35
Uruguay
(2005–07)
723 11.9 100 93 1.5 100 125 2.2 100 14 0.25 100 1 0.02 100 1 0.02 – 92 1.3 1
n, number of incident cases; ASR, age-standardized (World population) incidence rate per 100,000; MV, microscopic veriﬁcation; (–), no data available.
a Incidence rates were estimated using data from regional cancer registries.
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S126 R. Murillo et al. / Cancer Epidemiology 44S (2016) S121–S130intraepithelial lesion (HSIL), whereas countries with subnational
reports – such as Bolivia, Peru, Mexico, and Nicaragua – showed
follow-up rates of <60% [5]. Similarly, a different study from four
regions in Colombia revealed that only 62% of HSIL cytological
diagnoses underwent colposcopy, biopsy, and treatment as
indicated in a 6-month period following Pap smear results [15].
4. Discussion
For this analysis, national cancer registries were available for
Costa Rica and Uruguay; all other registries are regional while
mortality rates are national (Bolivia and French Guyana did not
have mortality data available). In addition, the reported incidence
in the included registries represents somewhat different periods.
In general, there was a wide variation of cervical cancer rates
across the region. Overall, rates were lower than the highest
incidence rates of cervical cancer in the world, e.g., Zimbabwe 86.7,
Malawi (76.3), China (71.8), and Uganda (54.3). Yet, speciﬁc
subnational regions showed higher incidence rates in Brazil
(Cuiabá, 36.5, Goiânia, 28.5), and Colombia (Pasto, 27.4) [11].
Mortality rates were lower than those observed in Sub-Saharan
Africa; however, the lowest rates observed in Chile, Uruguay, Brazil
and Costa Rica are higher than mortality rates in the most
developed regions of the world [1].
Only Argentina, Brazil, Chile and Costa Rica provided incidence
data for 10 years from several registries to produce time series.
Steady declines in cervical cancer incidence were also documented
in Cali (Colombia) over a period of 50 years (EAPC = 3% [95%
conﬁdence interval, 3.1, 2.6]) [17]. Likewise, Vaccarella et al.described declines in the incidence of cervical cancer in Brazil,
Colombia, Costa Rica and Ecuador since the 1980s to 2002 among
women 30–74 years old [18]. Recent analyses reported a decline
in cervical cancer mortality in Mexico (EAPC 1999–2007 = 5.1)
[19] and Colombia (EAPC 1998–2008 = 3.2) [20]. The greater
decrease in mortality, in addition to a signiﬁcant decline in
squamous-cell carcinoma for Chile and Costa Rica (starting year of
screening programs 1994 and 1995, respectively), might be an
indicator of a better performance of screening programs than that
observed in Argentina and Brazil (starting year 1997 and 1998,
respectively) where declines in incidence could be more related
to improvement in social determinants. This hypothesis is
supported by the fact that age-speciﬁc trends show an overall
decline in all age groups in Chile and Costa Rica, but very low or
no decline in Argentina and Brazil; for Costa Rica there is a clear
period effect between 1995 and 2000 when cervical cancer
mortality started reducing in most age groups (data not shown).
Unfortunately, data on performance of screening programs are
not available for all countries in the region, do not correspond to
time series related to incidence trends, and have relevant
differences among countries on target population and coverage
deﬁnition (Table 4).
Persistent infection of the cervix with high-risk HPV types has
been established as a necessary cause for the development of
cervical cancer [21]. There are several reports showing large
variability in HPV prevalence in Latin America and the Caribbean;
however, the results of these surveys should be interpreted
carefully given differences in the methodologies, biological speci-
mens, and genotyping techniques used. In particular, since HPV
Table 4
Prevention and early detection strategies in Latin America.
Country HPV vaccination programa Screening recommendations or guidelinesa Pap-smear coverage
(coverage/women
interviewed/interval)
Source
coverage
reportTarget
group/age
Vaccination
schedule
(months)
Delivery
strategy/
Starting year
Screening
technology
Target
age group
Screening
schedule
Argentina Girls/11 01-6 Mixed/2011 Pap-smear
HPV test
35–64
30–64
Every 3 years (1-1-3)
Every 3 years
60.5%/18 years and
older/past 2 years
ENFR 2011
Bolivia N/A – – Pap-smear
VIA
25–64
25–64
Every 3 years (1-1-3)
Every 3 years (1-1-3)
33.3%/15–49 years/
past 3 years
ENDSA 2008
Brazil Girls/11–13b 0660 Mixed/2014 Pap-smear 25–64 Every 3 years (1-1-3) 79.4%/25–59 years/
past 3 years
PN2008 CE
Chile Girls/4th school
grade
(9 years and
older)c
012 Schools/2014 Pap-smear 25–64 Every 3 years 57.7%/15 years and
older/past 3 years
ENS 2010
Colombia Girls/4th school
grade
(9 years and
older)c
0660 Schools/2011 Pap-smear
HPV test
VIA-VILI
21–69
30–64
30–59
Every 3 years (1-1-3)
Every 5 years
Every 3 years (rural)
71.3%/18–69 years/
past 3 years
ENDS 2010
Costa Rica N/A – – Pap-smear 20+ Annual N/A –
Cuba N/A – – Pap-smear 25–64 Every 3 years N/A –
Ecuador N/A – – N/A – – 38.9%/15–49 yearse/
past 2 years
ENDEMAIN
2004
El Salvador N/A – – Pap-smear
VIA
30–59
reproductive
age
Every 2 years
Every 2 years (rural)
66.7%/15–49 years/
past 2 years
FESAL 2008
Guatemala N/A – – Pap-smear
VIA
25–54
25–54
Every 3 years
Every 3 years
26.4%/30–49 years/
past 3 years
ENSMI 2002
Honduras N/A – – Pap-smear 30–59 Every 3 years (1-1-3) 41.2%/15–49 years/
past year
Murillo R
2008
Mexico Girls/5th school
grade
(11 years)c
0660 Mixed/2008 Pap-smear
HPV test
25–34
35–64
Every 3 years
Every 5 years
27.4%/20 years and
older/past year
ENS 2000
Nicaragua N/A – – Pap-smear
VIA
25–54
30–50
Every 3 years (1-1-3)
Every 3 years
23.3%/14–49 years/
past year
Murillo R
2008
Panama Girls/10 02-6 Mixed/2008 Pap-smear
HPV test
21–59
30–64
Every 2 yearsd
Every 3 years
N/A –
Paraguay Girls/10–11 01-6 Schools/2013 Pap-smear 25–49 Every 3 years (1-1-3) 51.1%/15–44 years/past
2 years
ENDSSR 2008
Peru Girls/10 3 doses in
6 months
Schools/2011 Pap-smear
HPV test
VIA
30–50
30–50
30–50
Annual
Every 5 years
Every 2 years
45.6%/15–49 years/
lifetime
Gutierrez C
2010
Uruguay Girls/12 02-6 Health centers/
2013
Pap-smear 30–64 Every 3 years 55.2%/18–69 years/
past 3 years
WHS 2003
Venezuela N/A – – Pap-smear 25–64 Every 3 years (1-1-3) N/A –
ENFR, Encuesta Nacional de Factores de Riesgo; ENDSA & ENDS, Encuesta Nacional de Demografía y Salud; PNAD, Pesquisa Nacional por Amostra de Domicílios – ENS:
Encuesta Nacional de Salud; WHS, World Health Survey; ENDEMAIN, Encuesta Demográﬁca y de Salud Materno Infantil; FESAL, Encuesta Nacional de Salud Familiar; ENSMI,
Encuesta Nacional de Salud Materno Infantil; ENDSSR, Encuesta Nacional de Demografía y Salud Sexual y Reproductiva; Murillo R 2008 [5]; Gutierrez C 2010 [16]. Only
nationwide population-based data were included.
a Source: Pan American Health Organization. Cancer country proﬁle. Washington DC: PAHO; 2013. Missing information in the PAHO report was complemented with data
from the ofﬁcial web site of the corresponding Ministry of Health.
b Temporary target population to ﬁnally target girls 11 years old.
c Girls in the school grade and the indicated age.
d Or starting 2 years after sexual debut.
e Sexually active women.
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the women included in the sample can create spurious data.
According to the Institut Català d'Oncologia (ICO) information
center, the HPV prevalence among women with normal cytology
reported from different studies has ranged between 3.8% in Peru
(18–65 years old) and 49.9% in Argentina (18–69 years old) [22]. As
expected, prevalence consistently increases with the severity of
the lesions, a situation more evident for certain HPV types such as
HPV16 and HPV18, resembling observations for other regions in
the world. The prevalence of these two HPV types is 4.5% in women
with normal cytology and 69.5% in women with invasive cervical
cancer.
The available data about prevalence of HPV16 and HPV18 across
CSA countries show some variability, ranging from 38.3% in Bolivia
to 85.2% in Chile for invasive cancers, and from 37.8% in Cuba to
71.0% in Chile for HSIL. These variations could have an impact on
cost-effectiveness of HPV vaccine programs, as well as on
performance of HPV-genotyping-based screening strategies;
however, limitations in the quality of data should be revised.
Countries in the region with the lowest invasive cancer incidence
rates have a higher prevalence of these two HPV types in invasive
cancer and vice versa (i.e., Chile cancer incidence 13.9 per
100,000 and HPV16/18 cancer prevalence 85.8%; Bolivia cancer
incidence 22.2 per 100,000 and HPV16/18 cancer prevalence
38.3%); this may be related to both a greater participation of other
HPV types in the spectrum of the disease and to a greater frequency
of multiple infections in high-risk populations. Similar ﬁndings
have been described when analyzing HPV prevalence worldwide
[23].
Multiple studies have indicated that early age at ﬁrst inter-
course is a risk factor for HPV infection and for invasive cervical
cancer [24]. There is a widespread belief that the age of occurrence
of cervical cancer is decreasing and the number of cervical cancer
cases in young women is increasing, and it has been proposed that
this is due to a declining age at ﬁrst intercourse [25]. Consequently,
several countries in CSA plan their screening programs according
to the median age at ﬁrst sexual intercourse. A report by WHO,
based on population-based cross-sectional surveys, showed a
slight increase in sexual activity among young Latin American
women with a consequent decline in the median age of sexual
debut [25]. Moreover, one study showed an association between
poverty and lower age for beginning sexual activity in Latin
America [26]; indeed, the percentage of 15–19-year-old women
who report having ever had sexual intercourse in the USA is
slightly lower than in Colombia (43% and 50%, respectively, in
2010) [27,28], the latter being one of the countries with the lowest
median age at sexual debut in the region. However, other countries
with lower per capita gross domestic product (GDP), such as
Honduras and Bolivia, show a lower percentage of younger women
reporting sexual intercourse (36% and 27%, respectively) [26].
Thus, according to the available information, there has been a
minor decline in median age at sexual debut, but differences
among countries are small.
As expected for a sexually transmitted infection, the main risk
factor for HPV infection is the number of sexual partners of the
women and the number of sexual partners of their partners. There
is limited information on the number of sexual partners in Latin
American countries. A review of epidemiological studies showed a
variation in the percentage of people having more than one sexual
partner in the previous year, from 20% in Colombia to 49% in Peru
[3]; however, this evidence does not correspond to population-
based data, making it difﬁcult to interpret. Recent reports from the
United Nations Programme on HIV/AIDS (UNAIDS) based on
population surveys showed a low frequency of multiple sexual
partnerships in the previous year for some of the countries with
the highest cervical cancer incidence rates in CSA (Nicaragua 1.5%,Peru 2.0%, Guatemala 3.7%, Honduras 4.4%); on the other hand,
several countries with the lowest incidence rates exhibit an
intermediate or high frequency of multiple sexual partners (Chile
9.2%, Uruguay 16.5%, Costa Rica 16.9%, Panama 45.1%, and Brazil
66.1%) [29]. These data indicate a low correlation between the
number of sexual partners and risk of cervical cancer at the
population level, probably pointing to the role of sexual behavior of
males but also to the effect of screening programs in cervical
cancer incidence.
HPV infection alone may not be sufﬁcient for the development
of cervical cancer; therefore other factors may also be involved in
the progression of this malignancy [30]. Increasing parity (full-
term pregnancies) is associated with risk of cervical carcinoma
among women with high-risk HPV, and it has been suggested that
fertility may have played a relevant role in the decline of cervical
cancer incidence in Latin America [3]. Total fertility rates have
dramatically decreased in all countries from CSA [31]. For the year
2013 no rates over 4 were present; Bolivia and Guatemala showed
the highest rates (3.8 and 3.2 per woman, respectively) while
Brazil, Chile, Costa Rica, and Cuba revealed the lowest rates
(ranging from 1.7 to 1.9 per woman).
As is the case with many other infectious diseases, poverty is
the strongest determinant of cervical cancer incidence and
mortality around the world [32], with developing countries
showing the highest incidence and mortality rates (15.7 and
8.3 versus 9.9 and 3.3 for the less developed and the most
developed regions respectively). The human development index
and poverty rates have shown a clear association (inverse and
direct respectively) with incidence and mortality, thus explaining
about 52% of cervical cancer variability globally [1,33]. With
exception of Venezuela, countries with the highest mortality rates
in the region correspond to those with the lowest per capita GDP.
Among countries with lowest mortality rates (below 10 per
100,000), Colombia and Cuba have lower per capita GDP than the
others, suggesting that factors other than poverty could be playing
a relevant role as determinants of disease mortality.
Since poverty is a strong determinant of social indicators such
as education, access to health care, and fertility rates, elucidating
the contribution of these factors to disease incidence and mortality
is particularly challenging. Disparities in cervical cancer mortality
by education level have been consistently described worldwide,
where illiteracy and primary schooling are associated with higher
cervical cancer rates than secondary or higher education;
concordantly, the level of education is related to screening
practices and sexual and reproductive health practices associated
with risk factors for invasive cancer [32,34]. Accordingly, in Brazil,
those with 7 years of schooling or less were associated with a
higher risk of advanced disease at diagnosis than those with more
than 7 years of education (OR = 1.4, 95%CI 1.3–1.5) [35]. In
Colombia, cervical cancer accounts for the highest cancer mortality
among those with primary or lower education than those with
tertiary education (college and university), (rate ratio
RR = 5.75 compared to college and university) [36]. In Mexico,
women living in rural environments had higher mortality rates
than those in urban areas (RR = 3.07); however, no linear
association was observed when mortality rates were examined
according to level of urbanization among Mexican states [37].
The Pap smear was introduced more than 5 decades ago and
continues to be the main screening tool for all countries in CSA
(Table 4). Progress in the implementation of HPV-based technolo-
gies is slow (ﬁve countries using HPV testing and eight countries
having started HPV vaccination), and similarly to other world
regions, HPV screening and vaccination in CSA (with the exception
of Paraguay) is taking place in countries with the lowest or
decreasing mortality rates. Despite the limitations on data quality
regarding the performance of vaccination and screening programs,
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indicates relative progress in program evaluation.
In this analysis we present a comprehensive description of the
current situation for cervical cancer incidence and mortality in
CSA. However, incidence data patterns must be interpreted with
caution because national incidence was estimated using aggregat-
ed data from local registries, most of which did not cover the entire
country; exceptions are the national cancer registries of Costa Rica
and Uruguay. Cancer registries in CSA may differ in completeness
and data quality. Microscopic veriﬁcation of cervical cancer
diagnosis was high, ranging from 89% to 100% (Table 2). These
high percentages were within the expected microscopic veriﬁca-
tion percentage for CSA, indicating accuracy of diagnosis. In
Mexico, however, 100% of the cases were veriﬁed microscopically,
suggesting over-reliance on pathology reports and probably
missing cases identiﬁed by other means [38]. Squamous-cell
carcinomas represented approximately 73% of all tumors of the
cervix, while less than 10% of the cases were classiﬁed as
unspeciﬁed cancers. The percentage of unspeciﬁed cases indicates
poor diagnostic precision [38]. The estimation of mortality rates
may be inﬂuenced by the quality of national death certiﬁcation
which, in some CSA countries, may be considered of medium or
low quality [39].
5. Conclusion
Cervical cancer is among the ﬁrst two or three most common
cancers in females in Central and South America. Despite the
steady declines in incidence of cervical cancer observed in
countries such as Argentina, Brazil, Chile and Costa Rica over
the past decade, mortality is high and remains stable in many
countries in the region. Clear declines in mortality trends were
observed across all age groups over 25 years after the mid-1990s
only in Chile and Costa Rica; thus, such declines are probably due to
the adoption of early detection programs in these countries.
Additionally, approximately 80% of the cervical carcinoma cases
diagnosed in the region were squamous-cell carcinoma and 12%
were adenocarcinomas. Declines in cervical squamous-cell carci-
noma were observed in Chile and Costa Rica, reinforcing the
hypothesis of a better performance of screening programs for these
tumor types. In contrast, declines in Argentina and Brazil are more
likely to be related to socioeconomic determinants since they are
not present through all age groups undergoing screening.
However, Argentina and Brazil report higher screening coverage
than Chile. The lack of correlation between screening coverage and
mortality reduction has been previously described for Latin
America [5]; thus, beyond the limitations of self-reported
screening, it is likely that better organized programs favor better
follow-up of positive screened women, causing a greater impact on
cancer incidence and mortality.
Technological developments in primary and secondary preven-
tion offer new opportunities for intervention. Despite several years
of effort with cytology-based screening, cervical cancer remains an
important public health problem in Central and South America;
however, in 2015 almost half the countries have introduced HPV
vaccination, and around the same number started alternative
approaches for screening of precancerous lesions; thus, it is
expected that better health outcomes for women in the region will
be observed in the forthcoming years. To assess such impact,
information systems and data collection should improve all across
the region; since there are signiﬁcant differences in level of
development and availability of resources, various alternatives –
including routine data, case audits, cross-sectional surveys, and
speciﬁc studies – should be considered according to speciﬁc
conditions and suitability for every setting.Conﬂict of interest
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